Blog
RSS FeedPosted by Michael Wonder on 30 Sep 2025
Schedule of Pharmaceutical Benefits - 1 October 2025
1 October 2025 - The October 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Sep 2025
Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria
30 September 2025 - Remibrutinib also in clinical development for chronic inducible urticaria, food allergy, and hidradenitis suppurativa, expanding Novartis Immunology ...
Posted by Michael Wonder on 30 Sep 2025
Pfizer reaches landmark agreement with US Government to lower drug costs for American patients
30 September 2025 - Voluntary agreement meets the President’s four requests while also protecting the US ecosystem responsible for America’s leadership ...
Posted by Michael Wonder on 30 Sep 2025
Novo Nordisk submits biologics license application to FDA for Mim8; an investigational, prophylaxis treatment for people living with haemophilia A with or without inhibitors
29 September 2025 - In haemophilia A, denecimig is designed to help the body form blood clots more effectively and was ...
Posted by Michael Wonder on 30 Sep 2025
US FDA approves Tremfya (guselkumab) for the treatment of paediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
29 September 2025 - Approval was based on PROTOSTAR study, which showed paediatric patients receiving Tremfya achieved high levels of ...
Posted by Michael Wonder on 29 Sep 2025
AbbVie announces UK pricing strategy for Elahere (mirvetuximab soravtansine-gynx)
29 September 2025 - The list price will be consistent with the US to reflect the value of the innovation. ...
Posted by Michael Wonder on 29 Sep 2025
New life changing medicines listed on the PBS
28 September 2025 - From 1 October 2025, Australians affected by breast cancer and rare kidney disease will have access ...
Posted by Michael Wonder on 29 Sep 2025
EMA recommends marketing approval of Gobivaz, Alvotech’s proposed biosimilar to Simponi (golimumab) with Advanz Pharma as commercialisation partner
22 September 2025 - Alvotech and Advanz Pharma today announced that the EMA's CHMP has adopted a positive opinion recommending approval ...
Posted by Michael Wonder on 28 Sep 2025
Donald Trump is waging war on sky-high drug prices. Can he win?
28 September 2025 - Big Pharma has a big headache: Donald Trump. Lately drugmakers have had to contend with the ...
Posted by Michael Wonder on 27 Sep 2025
Major breast cancer treatment cost slashed under new PBS listing
28 September 2025 - Thousands of women will pay significantly less for treatment after the Federal Government listed a leading ...
Posted by Michael Wonder on 27 Sep 2025
Health Minister Mark Butler says PBS not for negotiation, Donald Trump announced 100 pc tariff on pharmaceutical goods
26 September 2025 - Health Minister Mark Butler says Australia’s PBS will be protected at all costs, despite a pending ...
Posted by Michael Wonder on 26 Sep 2025
Crinetics announces FDA approval of Palsonify (paltusotine) for the treatment of adults with acromegaly
25 September 2025 - Approval based on data from two pivotal Phase 3 trials where Palsonify was well tolerated and resulted ...
Posted by Michael Wonder on 26 Sep 2025
AbbVie submits new drug application to US FDA for tavapadon for the treatment of Parkinson's fisease
26 September 2025 - Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's ...
Posted by Michael Wonder on 26 Sep 2025
Evkeeza (evinacumab-dgnb) ANGPTL3 antibody approved in the US for children as young as 1 year old with ultra-rare form of high cholesterol
26 September 2025 - Regeneron Pharmaceuticals today announced that the US FDA has approved Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct ...
Posted by Michael Wonder on 26 Sep 2025
Vertex announces key advancements across kidney portfolio
25 September 2025 - Vertex announced today that the FDA has granted breakthrough therapy designation to povetacicept for the treatment of ...